Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Baricitinib - Eli Lilly and Company/Incyte Corporation

Drug Profile

Baricitinib - Eli Lilly and Company/Incyte Corporation

Alternative Names: INCB 028050; INCB 28050; LY 3009104; Olumiant

Latest Information Update: 02 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Incyte Corporation
  • Developer Eli Lilly; Eli Lilly and Company; Incyte Corporation; Natco Pharma
  • Class Acetonitriles; Anti-inflammatories; Antipsoriatics; Antirheumatics; Azetidines; Eye disorder therapies; Pyrazoles; Pyrimidines; Pyrroles; Skin disorder therapies; Small molecules
  • Mechanism of Action Janus kinase 1 inhibitors; Janus kinase 2 inhibitors; TYK2 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Systemic lupus erythematosus
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Alopecia areata; Atopic dermatitis; Rheumatoid arthritis
  • Registered COVID 2019 infections
  • Phase III Juvenile rheumatoid arthritis; Uveitis
  • Phase II/III Aicardi-Goutieres syndrome; Hereditary autoinflammatory diseases
  • Phase II Giant cell arteritis; Myositis; Polymyalgia rheumatica; Primary biliary cirrhosis; Systemic lupus erythematosus
  • Discontinued Diabetic nephropathies; Psoriasis; Psoriatic arthritis

Most Recent Events

  • 30 Jan 2024 Registered for Alopecia areata in Canada (PO)
  • 25 Sep 2023 University of Manchester in collaboration with Eli Lilly and Company completes phase-II MYOJAK trial in Myositis in United Kingdom (PO) (EudraCT2019-003868-42) (NCT04208464)
  • 30 Aug 2023 Eli Lilly and Company completes a phase II trial in Polymyalgia rheumatica in France (PO, Tablet) (NCT04027101)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top